Reduction in size of prolactin-secreting tumours in men treated with pergolide.
- 14 August 1982
- Vol. 285 (6340), 465-467
- https://doi.org/10.1136/bmj.285.6340.465
Abstract
The effect of pergolide mesylate was studied in two previously untreated men with large prolactinomas and exceptionally high prolactin concentrations. The study was designed to determine whether pergolide would be effective in alleviating symptoms, correcting hormonal abnormalities and shrinking the tumour. Starting with 50 micrograms daily the dose of pergolide was slowly increased over 10 weeks to 1 mg once daily, when repeat assessment was performed. Both patients reported complete relief of symptoms, with no side effects. Serum prolactin concentration was suppressed to normal in both subjects, and evidence to suggest tumour shrinkage was observed. Pergolide appears to be effective treatment for men with large prolactinomas.This publication has 10 references indexed in Scilit:
- HYPERPROLACTINAEMIA IN MEN?RESPONSE TO BROMOCRIPTINE THERAPYThe Lancet, 1982
- TREATMENT OF HYPERPROLACTINAEMIA WITH PERGOLIDE MESYLATE: ACUTE EFFECTS AND PRELIMINARY EVALUATION OF LONG-TERM TREATMENTThe Lancet, 1981
- TWO NEW DOPAMINE AGONISTS THAT ARE LONG ACTING IN VIVO BUT SHORT ACTING IN VITROClinical Endocrinology, 1980
- Pergolide Mesylate: A Potent Day-Long Inhibitor of Prolactin in Rhesus Monkeys and Patients with Parkinson's Disease*Journal of Clinical Endocrinology & Metabolism, 1980
- Interaction of pergolide with central dopaminergic receptors.Proceedings of the National Academy of Sciences, 1980
- Pergolide, a potent long-acting dopamine-receptor agonistClinical Pharmacology & Therapeutics, 1980
- Effects of bromocriptine on pituitary tumour size.BMJ, 1979
- Pharmacologic Effects in Man of a Potent, Long-Acting Dopamine Receptor AgonistScience, 1979
- Regression of pituitary tumors, a possible effect of bromergocryptineThe American Journal of Medicine, 1979